Biofil Chemicals & Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.59×	0.81×	0.76×	0.82×	0.71×
	1.61×	9.14×	1.57×	2.07×	1.07×
	1.5%	1.3%	1.4%	1.0%	2.5%
	0.61×	0.61×	0.68×	1.02×	1.20×
	1.99×	1.99×	2.71×	2.59×	1.82×
	1.7%	11.9%	3.1%	4.7%	4.1%
	13.8%	13.8%	3.0%	4.0%	3.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

BIOFILCHEM₹29.26

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersMANGALAM VINEETLAB LASA ORTINGLOBE KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹47.6 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.71	0.82	0.76	0.81	0.59
Interest Burden (Pretax/EBIT) ×	1.07	2.07	1.57	9.14	1.61
EBIT Margin %	2.46	1.04	1.40	1.33	1.49
Asset Turnover ×	1.20	1.02	0.68	0.61	0.61
Financial Leverage (Assets/Equity) ×	1.82	2.59	2.71	1.99	1.99
ROE (5-step product, year-end total equity) %	4.06	4.67	3.08	11.89	1.71
ROE (owners' profit / average owners' equity) %	3.34	4.00	3.02	13.81	13.81

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.